Should I buy or sell Stoke Therapeutics stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" STOK shares. View STOK analyst ratings or view top-rated stocks .

What is Stoke Therapeutics' stock price target for 2024?

9 Wall Street research analysts have issued 12-month target prices for Stoke Therapeutics' shares. Their STOK share price targets range from $12.00 to $35.00. On average, they predict the company's share price to reach $19.63 in the next twelve months. This suggests a possible upside of 67.4% from the stock's current price. View analysts price targets for STOK or view top-rated stocks among Wall Street analysts .

How have STOK shares performed in 2024?

Stoke Therapeutics' stock was trading at $5.26 on January 1st, 2024. Since then, STOK shares have increased by 122.8% and is now trading at $11.72. View the best growth stocks for 2024 here .

Are investors shorting Stoke Therapeutics?

Stoke Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 4,950,000 shares, an increase of 39.4% from the March 15th total of 3,550,000 shares. Based on an average daily trading volume, of 1,010,000 shares, the short-interest ratio is currently 4.9 days. Currently, 15.0% of the shares of the company are short sold. View Stoke Therapeutics' Short Interest .

When is Stoke Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our STOK earnings forecast .

How were Stoke Therapeutics' earnings last quarter?

Stoke Therapeutics, Inc. (NASDAQ:STOK) released its earnings results on Monday, March, 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.02. The business had revenue of $2.80 million for the quarter, compared to analysts' expectations of $3.70 million.

What ETFs hold Stoke Therapeutics' stock?

ETFs with the largest weight of Stoke Therapeutics (NASDAQ:STOK) stock in their portfolio include Morningstar US Small Growth (MSGR) and WisdomTree BioRevolution Fund (WDNA) . Global X Genomics & Biotechnology ETF (GNOM) .

What other stocks do shareholders of Stoke Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS) , Editas Medicine (EDIT) , Alector (ALEC) , LogicBio Therapeutics (LOGC) , NVIDIA (NVDA) , Precision BioSciences (DTIL) , Kaleido Biosciences (KLDO) , Homology Medicines (FIXX) , Marvell Technology (MRVL) and Invitae (NVTA) .

When did Stoke Therapeutics IPO?

Stoke Therapeutics (STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

How do I buy shares of Stoke Therapeutics?

Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:STOK

Stoke Therapeutics (STOK) Stock Price, News & Analysis

→ Top 5 Tech Stocks to Buy for 2024 (From Daily Market Alerts) (Ad)

Free STOK Stock Alerts

$11.72

-0.73 (-5.86%)

(As of 04/17/2024 ET)

Compare

Today's Range: $11.63
▼
$12.97
50-Day Range: $4.12
▼
$14.17
52-Week Range: $3.35
▼
$16.40

Volume: 791,111 shs
Average Volume: 970,511 shs
Market Capitalization: $542.64 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.63

Get Stoke Therapeutics alerts:

Stoke Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.78 Rating Score
Upside/Downside: 67.4% Upside
$19.63 Price Target
Short Interest: Bearish
15.01% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.59
Upright™ Environmental Score
News Sentiment: 0.78
Based on 19 Articles This Week
Insider Trading: Selling Shares
$223,115 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.28) to ($2.71) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.22 out of 5 stars

Medical Sector

130th out of 913 stocks

Pharmaceutical Preparations Industry

40th out of 396 stocks

4.4

Analyst's Opinion

Consensus Rating
Stoke Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Stoke Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
15.01% of the float of Stoke Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Stoke Therapeutics has a short interest ratio ("days to cover") of 4.9.
Change versus previous month
Short interest in Stoke Therapeutics has recently increased by 39.44%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Stoke Therapeutics does not currently pay a dividend.
Dividend Growth
Stoke Therapeutics does not have a long track record of dividend growth.

4.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Stoke Therapeutics has received a 77.13% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Stoke Therapeutics is -0.59.

3.8

News and Social Media Coverage

News Sentiment
Stoke Therapeutics has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.35 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 19 news articles for Stoke Therapeutics this week, compared to 4 articles on an average week.
Search Interest
23 people have searched for STOK on MarketBeat in the last 30 days. This is an increase of 475% compared to the previous 30 days.
MarketBeat Follows
10 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $223,115.00 in company stock.
Percentage Held by Insiders
12.30% of the stock of Stoke Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.28) to ($2.71) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Stoke Therapeutics is -4.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Stoke Therapeutics is -4.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Stoke Therapeutics has a P/B Ratio of 3.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Biden out June 13; Kamala won’t replace him?

On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.

See who it is HERE.

About Stoke Therapeutics Stock (NASDAQ:STOK)

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

STOK Stock Price History

30 days | 90 days | 365 days | Advanced Chart

STOK Stock News Headlines

April 2, 2024 | insidertrades.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells $67,663.20 in Stock

March 20, 2024 | insidertrades.com

Insider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells 2,349 Shares of Stock

April 18, 2024 | Paradigm Press (Ad)

Biden out June 13; Kamala won’t replace him?

On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.

April 17, 2024 | finance.yahoo.com

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

April 17, 2024 | businesswire.com

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

April 17, 2024 | msn.com

The focus inside the Stoke City changing room ahead of Plymouth Argyle and 'biggest game of season'

April 13, 2024 | americanbankingnews.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Short Interest Update

April 13, 2024 | americanbankingnews.com

Stoke Therapeutics (NASDAQ:STOK) Stock Rating Reaffirmed by Needham & Company LLC

April 18, 2024 | Paradigm Press (Ad)

Biden out June 13; Kamala won’t replace him?

On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.

April 13, 2024 | americanbankingnews.com

Stoke Therapeutics, Inc. (NASDAQ:STOK) Forecasted to Earn Q2 2024 Earnings of ($0.43) Per Share

April 13, 2024 | americanbankingnews.com

Research Analysts Offer Predictions for Stoke Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:STOK)

April 12, 2024 | benzinga.com

Stoke Therapeutics Stock (NASDAQ:STOK), Analyst Ratings, Price Targets, Predictions

April 12, 2024 | markets.businessinsider.com

Buy Rating Justified by Stoke Therapeutics’ Promising Pipeline and Strategic Market Positioning

April 8, 2024 | americanbankingnews.com

Stoke Therapeutics, Inc. Forecasted to Post Q1 2024 Earnings of ($0.60) Per Share (NASDAQ:STOK)

April 4, 2024 | businesswire.com

Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

April 4, 2024 | markets.businessinsider.com

Assessing Stoke Therapeutics: Insights From 6 Financial Analysts

April 4, 2024 | seekingalpha.com

Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist

April 3, 2024 | markets.businessinsider.com

Strong Buy Rating for Stoke Therapeutics’ STK-001 Backed by Positive KOL Feedback and Revolutionary Potential in Dravet Syndrome Treatment

April 1, 2024 | msn.com

Stoke Stock (NASDAQ:STOK) Gains on Drug Update; Is There More Upside Left?

March 27, 2024 | businesswire.com

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

March 27, 2024 | markets.businessinsider.com

Stoke Therapeutics’ STK-001 Shows Promise: Buy Rating Affirmed Amid Positive Clinical and Financial Outlook

March 27, 2024 | marketwatch.com

Stoke Therapeutics Shares Extend Gains to 52-Week High, Plans for $75M Offering

March 27, 2024 | bizjournals.com

Stoke Therapeutics plans $75M public offering on heels of Dravet trial results

March 27, 2024 | msn.com

What's Going On With Stoke Therapeutics Stock Tuesday?

March 27, 2024 | msn.com

Shares in Bedford-based Stoke Therapeutics surge after encouraging results in studies of epilepsy medicine

March 26, 2024 | businesswire.com

Stoke Therapeutics Announces Proposed Public Offering

March 26, 2024 | msn.com

TD Cowen ups Stoke to buy on updated data for epilepsy drug

See More Headlines

Receive STOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/25/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:STOK
CUSIP: N/A
CIK: 1623526
Web: www.stoketherapeutics.com
Phone: (781) 430-8200
Fax: N/A
Employees: 110
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $19.63
High Stock Price Target: $35.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +67.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.78
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.37)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-104,700,000.00
Net Margins: N/A
Pretax Margin: -1,192.47%
Return on Equity: -56.86%
Return on Assets: -41.59%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.99
Quick Ratio: 6.99

Sales & Book Value

Annual Sales: $8.78 million
Price / Sales: 61.80
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.57 per share
Price / Book: 3.28

Miscellaneous

Outstanding Shares: 46,300,000
Free Float: 40,609,000
Market Cap: $542.64 million
Optionable: Optionable
Beta: 0.77

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Edward M. Kaye M.D. (Age 75)
Ph.D., CEO & Director
Comp: $931.21k
Dr. Adrian R. Krainer Ph.D. (Age 65)
Co-Founder & Independent Director
Comp: $44k
Mr. Stephen J. Tulipano CPA (Age 65)
MBA, Chief Financial Officer
Comp: $619.09k
Dr. Barry S. Ticho FACC (Age 63)
M.D., Ph.D., Chief Medical Officer
Comp: $688.83k
Ms. Isabel Aznarez Ph.D. (Age 51)
Co-Founder & Group VP of Discovery Research
Dr. Huw M. Nash Ph.D. (Age 57)
COO & Chief Business Officer
Comp: $429.67k
Mr. Eric Rojas
Head of Investor Relations
Mr. Jonathan Allan J.D. (Age 34)
Corporate Secretary & General Counsel
Ms. Dawn Kalmar (Age 46)
Chief Communications Officer
Ms. Joan Wood
Chief Human Resources Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

STOK Stock Analysis - Frequently Asked Questions

Should I buy or sell Stoke Therapeutics stock right now?: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" STOK shares.
View STOK analyst ratings or view top-rated stocks.
What is Stoke Therapeutics' stock price target for 2024?: 9 Wall Street research analysts have issued 12-month target prices for Stoke Therapeutics' shares. Their STOK share price targets range from $12.00 to $35.00. On average, they predict the company's share price to reach $19.63 in the next twelve months. This suggests a possible upside of 67.4% from the stock's current price.
View analysts price targets for STOK or view top-rated stocks among Wall Street analysts.
How have STOK shares performed in 2024?: Stoke Therapeutics' stock was trading at $5.26 on January 1st, 2024. Since then, STOK shares have increased by 122.8% and is now trading at $11.72.
View the best growth stocks for 2024 here.
Are investors shorting Stoke Therapeutics?: Stoke Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 4,950,000 shares, an increase of 39.4% from the March 15th total of 3,550,000 shares. Based on an average daily trading volume, of 1,010,000 shares, the short-interest ratio is currently 4.9 days. Currently, 15.0% of the shares of the company are short sold.
View Stoke Therapeutics' Short Interest.
When is Stoke Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our STOK earnings forecast.
How were Stoke Therapeutics' earnings last quarter?: Stoke Therapeutics, Inc. (NASDAQ:STOK) released its earnings results on Monday, March, 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.02. The business had revenue of $2.80 million for the quarter, compared to analysts' expectations of $3.70 million.

What ETFs hold Stoke Therapeutics' stock?: ETFs with the largest weight of Stoke Therapeutics (NASDAQ:STOK) stock in their portfolio include Morningstar US Small Growth (MSGR) and WisdomTree BioRevolution Fund (WDNA).Global X Genomics & Biotechnology ETF (GNOM).
What other stocks do shareholders of Stoke Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA).
When did Stoke Therapeutics IPO?: Stoke Therapeutics (STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.
How do I buy shares of Stoke Therapeutics?: Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:STOK) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Stoke Therapeutics (STOK) Stock Price, News & Analysis

Stoke Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Stoke Therapeutics Stock (NASDAQ:STOK)

STOK Stock Price History

STOK Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

STOK Stock Analysis - Frequently Asked Questions

Overall MarketRank^™